By Anna Ringstrom and Maggie Fick STOCKHOLM/LONDON (Reuters) -Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ...
It's been six months since I accidentally poisoned myself with a weight-loss jab I shouldn't have taken. But while the memory ...
Find insight on Novo Holdings, Malaysian glove sector and more in the latest Market Talks covering health care.
Copenhagen: Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight loss treatments Ozempic and Wegovy, said Monday it was investing ...
Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, said Monday it was ...
Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, which have gained ...
Some people are not taking weight-loss medications responsibly, the physician says, and don't realize their full implications ...
Novo Holdings has completed regulatory conditions for its $16.5 billion acquisition of Catalent, aiming to increase production of Wegovy, a weight-loss drug. The deal includes selling three Catalent ...
On the other hand, the nature of its industry means that there will often be solid new reasons to be a bit more cautious ...
Eli Lilly (LLY 0.86%) and Novo Nordisk (NVO -1.53%) have competed for decades. They're both leaders in the areas of insulin ...
Over 18 months, people taking Zepbound lost more weight on average than those on Wegovy, according to the first head-to-head ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback